# WIA-BIO-020 — Phase 3: Protocol

> Regenerative-medicine canonical Phase 3: protocols (cell-prep + differentiation + implantation + vascularization + tumourigenicity-safety).

# WIA-BIO-020: Regenerative Medicine Specification v1.0

> **Standard ID:** WIA-BIO-020
> **Version:** 1.0.0
> **Published:** 2025-12-26
> **Status:** Active
> **Authors:** WIA Regenerative Medicine Research Group

---

## Table of Contents

1. [Introduction](#1-introduction)
2. [Stem Cell Types and Classification](#2-stem-cell-types-and-classification)
3. [Regeneration Mechanisms](#3-regeneration-mechanisms)
4. [Tissue Engineering and Scaffolds](#4-tissue-engineering-and-scaffolds)
5. [Growth Factor Delivery Systems](#5-growth-factor-delivery-systems)
6. [Clinical Applications](#6-clinical-applications)
7. [Regulatory Requirements](#7-regulatory-requirements)
8. [Implementation Guidelines](#8-implementation-guidelines)
9. [Safety Protocols](#9-safety-protocols)
10. [References](#10-references)

---


## 3. Regeneration Mechanisms

### 3.1 Cellular Regeneration Pathways

#### 3.1.1 Proliferation

**Cell Cycle Regulation**:
```
G1 → S → G2 → M → G1
```

**Key Regulators**:
- Cyclins (D, E, A, B)
- CDKs (Cyclin-Dependent Kinases)
- CDK inhibitors (p21, p27, p16)

**Proliferation Rate**:
```
P = N₀ × e^(rt)
```

Where:
- `P` = Cell population at time t
- `N₀` = Initial cell number
- `r` = Growth rate
- `t` = Time

#### 3.1.2 Differentiation

**Lineage Commitment Factors**:
- Transcription factors (RUNX2 for bone, PPARG for adipose)
- Epigenetic modifications (DNA methylation, histone acetylation)
- Signaling pathways (Wnt, BMP, Notch, Hedgehog)

**Differentiation Efficiency**:
```
D_eff = (N_differentiated / N_total) × 100%
```

Target efficiency: >80% for clinical applications

#### 3.1.3 Migration and Homing

**Chemotactic Gradient**:
```
v = μ × ∇C
```

Where:
- `v` = Migration velocity
- `μ` = Chemotactic sensitivity
- `∇C` = Concentration gradient

**Homing Factors**:
- SDF-1/CXCR4 axis
- VEGF (Vascular Endothelial Growth Factor)
- Selectins and integrins

### 3.2 Tissue Regeneration Rate

**Mathematical Model**:
```
dT/dt = α × C × G - β × T
```

Where:
- `T` = Tissue volume
- `C` = Cell density
- `G` = Growth factor concentration
- `α` = Regeneration coefficient
- `β` = Degradation coefficient

**Integration Score**:
```
I = (V_integrated / V_total) × F_vascular × F_mechanical
```

Target integration score: I ≥ 0.8

### 3.3 Angiogenesis (Blood Vessel Formation)

**VEGF Signaling**:
```
VEGF + VEGFR2 → ERK1/2, Akt → Endothelial proliferation
```

**Vessel Density**:
```
D_vessel = N_vessels / Area (vessels/mm²)
```

Healthy tissue: 200-400 vessels/mm²

**Sprouting Model**:
```
Tip cells → VEGF gradient
Stalk cells → Lumen formation
Pericytes → Vessel stabilization
```

---



## 4. Tissue Engineering and Scaffolds

### 4.1 Scaffold Design Principles

**Essential Properties**:
1. **Biocompatibility**: No toxic or inflammatory response
2. **Biodegradability**: Controlled degradation matching tissue growth
3. **Porosity**: 70-90% for nutrient diffusion
4. **Mechanical Strength**: Match native tissue
5. **Surface Chemistry**: Support cell adhesion

### 4.2 Scaffold Materials

#### 4.2.1 Natural Polymers

| Material | Source | Degradation | Applications |
|----------|--------|-------------|--------------|
| Collagen | Animal tissue | Enzymatic (MMP) | Skin, bone, cartilage |
| Gelatin | Denatured collagen | Enzymatic | Drug delivery, wound healing |
| Chitosan | Crustacean shells | Lysozyme | Cartilage, wound dressing |
| Hyaluronic Acid | ECM | Hyaluronidase | Cartilage, dermal fillers |
| Fibrin | Blood clotting | Plasmin | Wound healing, cell delivery |
| Alginate | Seaweed | Non-enzymatic | Cell encapsulation |

#### 4.2.2 Synthetic Polymers

| Material | Type | Degradation Time | Applications |
|----------|------|------------------|--------------|
| PLA | Polyester | 12-24 months | Bone fixation, sutures |
| PLGA | Copolymer | 1-12 months | Drug delivery, scaffolds |
| PCL | Polyester | 24-36 months | Long-term implants |
| PEG | Hydrophilic | Stable/tunable | Hydrogels, drug release |
| PU | Polyurethane | Variable | Cardiovascular devices |

### 4.3 Scaffold Fabrication Methods

**3D Printing (Bioprinting)**:
```
Resolution: 50-200 μm
Print speed: 1-10 mm/s
Cell viability: >85% post-print
Layer thickness: 100-500 μm
```

**Electrospinning**:
```
Fiber diameter: 50 nm - 5 μm
Voltage: 10-30 kV
Flow rate: 0.1-5 ml/h
Porosity: 70-95%
```

**Freeze Drying**:
```
Freezing: -20°C to -80°C
Primary drying: -10°C, <100 mTorr
Secondary drying: 20°C, <50 mTorr
Pore size: 50-300 μm
```

### 4.4 Scaffold Characterization

**Porosity Measurement**:
```
P = (1 - ρ_scaffold / ρ_material) × 100%
```

**Pore Size Distribution**: 100-500 μm for bone, 50-150 μm for cartilage

**Mechanical Testing**:
```
Young's Modulus (E) = σ / ε
```

Target values:
- Bone: 10-20 GPa
- Cartilage: 0.5-2 MPa
- Skin: 0.1-1 MPa
- Blood vessels: 1-10 MPa

**Degradation Rate**:
```
M_remaining(t) = M₀ × e^(-kt)
```

Where:
- `M_remaining` = Remaining mass
- `M₀` = Initial mass
- `k` = Degradation rate constant
- `t` = Time

---



## 6. Clinical Applications

### 6.1 Cardiac Regeneration

**Target**: Post-myocardial infarction (MI) heart repair

**Cell Sources**:
- iPSC-derived cardiomyocytes
- Cardiac progenitor cells
- MSCs (paracrine effects)

**Delivery Methods**:
- Direct injection into myocardium
- Intracoronary infusion
- Cardiac patch application

**Protocols**:
```
Cell dose: 2-5 × 10⁸ cells
Delivery timing: 2-4 weeks post-MI
Growth factors: VEGF, FGF-2, IGF-1
Scaffold: Fibrin or alginate hydrogel
```

**Success Metrics**:
- Ejection fraction improvement: >5%
- Infarct size reduction: >15%
- Vessel density increase: >30%

### 6.2 Neural Regeneration

**Target**: Spinal cord injury, stroke, neurodegenerative diseases

**Cell Sources**:
- Neural progenitor cells (NPCs)
- iPSC-derived neurons
- Schwann cells (peripheral nerves)

**Differentiation**:
```
iPSCs → Neural rosettes → NPCs → Neurons/Astrocytes/Oligodendrocytes
```

**Growth Factors**:
- BDNF (Brain-Derived Neurotrophic Factor)
- NGF (Nerve Growth Factor)
- NT-3 (Neurotrophin-3)
- GDNF (Glial-Derived Neurotrophic Factor)

**Protocols**:
```
Cell dose: 5-10 × 10⁶ cells
Injection: Intraspinal or intracerebral
Scaffold: Hyaluronic acid or chitosan
Immunosuppression: Cyclosporine or tacrolimus
```

**Success Metrics**:
- Axon regeneration: >500 μm
- Functional recovery: ASIA scale improvement
- Electrophysiology: Restored conduction

### 6.3 Bone Regeneration

**Target**: Non-union fractures, critical-size defects, osteoporosis

**Cell Sources**:
- BM-MSCs
- Adipose-derived MSCs
- Periosteal cells

**Osteogenic Differentiation**:
```
MSCs + BMP-2 + Dexamethasone + β-glycerophosphate + Ascorbic acid
    → Osteoblasts → Mineralized matrix
```

**Scaffold Requirements**:
- Material: Hydroxyapatite, β-TCP, PLGA
- Porosity: 70-80%
- Pore size: 200-400 μm
- Compressive strength: >5 MPa

**Protocols**:
```
Cell seeding: 5 × 10⁶ cells/cm³
BMP-2 dose: 100-200 μg
Culture time: 7-14 days in vitro
Implantation: Direct surgical placement
```

**Success Metrics**:
- Bone volume/Total volume (BV/TV): >40%
- Mechanical strength: >70% native bone
- Complete bridging: 3-6 months

### 6.4 Cartilage Repair

**Target**: Osteoarthritis, focal cartilage defects

**Cell Sources**:
- Autologous chondrocytes (ACI)
- MSCs
- iPSC-derived chondrocytes

**Chondrogenic Differentiation**:
```
MSCs + TGF-β3 + BMP-6 + Dexamethasone → Chondrocytes
    → Collagen II, Aggrecan, SOX9⁺
```

**Protocols**:
```
Cell dose: 1-5 × 10⁶ cells/cm²
Scaffold: Collagen type I/III or hyaluronic acid
Growth factors: TGF-β3 (10 ng/ml), BMP-6 (100 ng/ml)
Implantation: Arthroscopic or open surgery
```

**Success Metrics**:
- ICRS (International Cartilage Repair Society) score: ≥8/12
- Collagen II expression: >70%
- GAG content: >60% native cartilage

### 6.5 Skin Regeneration

**Target**: Burns, chronic wounds, diabetic ulcers

**Cell Sources**:
- Autologous keratinocytes
- Fibroblasts
- MSCs

**Bioengineered Skin**:
```
Dermal layer: Fibroblasts + collagen scaffold
Epidermal layer: Keratinocytes + fibrin glue
Full-thickness: Bilayer construct
```

**Protocols**:
```
Cell expansion: 2-3 weeks
Keratinocyte density: 5 × 10⁴ cells/cm²
Fibroblast density: 1 × 10⁴ cells/cm²
Growth factors: EGF, KGF, PDGF
```

**Success Metrics**:
- Wound closure: >90% at 3 weeks
- Scar formation: Minimal (Vancouver Scar Scale <5)
- Pigmentation: Restored within 6 months

---



## 9. Safety Protocols

### 9.1 Pre-Clinical Testing Checklist

- [ ] In vitro biocompatibility (ISO 10993)
- [ ] Tumorigenicity assay (nude mice)
- [ ] Biodistribution study
- [ ] Toxicology (acute, subacute, chronic)
- [ ] Immunogenicity assessment
- [ ] Off-target differentiation check
- [ ] Long-term genomic stability

### 9.2 Clinical Safety Monitoring

**Adverse Events**:
- Immune rejection
- Infection
- Tumor formation
- Ectopic tissue formation
- Thrombosis

**Monitoring Schedule**:
```
Week 1: Daily
Week 2-4: Every 3 days
Month 2-6: Weekly
Month 7-12: Monthly
Year 2+: Quarterly
```

**Biomarkers**:
- Complete blood count (CBC)
- Liver function tests (ALT, AST)
- Kidney function (creatinine, BUN)
- Inflammation markers (CRP, IL-6)
- Tumor markers (AFP, CEA, if applicable)

### 9.3 Dose Escalation

**3+3 Design**:
```
Level 1: 1 × 10⁶ cells (3 patients)
Level 2: 5 × 10⁶ cells (3 patients)
Level 3: 1 × 10⁷ cells (3 patients)
Level 4: 5 × 10⁷ cells (3 patients)
```

**DLT Criteria** (Dose-Limiting Toxicity):
- Grade ≥3 adverse event
- Serious adverse event (SAE)
- Death within 30 days

### 9.4 Long-Term Follow-Up

**Duration**: Minimum 5 years for cell therapy, 15 years for gene therapy

**Assessments**:
- Functional outcomes (disease-specific)
- Quality of life (SF-36, EQ-5D)
- Imaging (MRI, CT, ultrasound)
- Biopsy (if indicated)
- Genetic stability (karyotype, CGH array)

---




---

## A.1 Cell-preparation protocol

Cell-preparation protocol covers the donor-screening envelope (FDA 21 CFR 1271 Subpart C eligibility determination + EU Directives 2004/23/EC + 2006/17/EC; KFDA Notification 2021-92 equivalents), the tissue-procurement envelope (informed consent + Institutional Review Board approval + chain-of-custody from the procurement site), the isolation envelope (mechanical + enzymatic dissociation as appropriate per cell source), the expansion envelope (passage limits per cell type — typically <p10 for clinical-grade MSC), the cryopreservation envelope (slow-controlled-rate freeze with the operator's documented cryo-medium recipe), and the post-thaw recovery envelope (viability testing + immediate-use vs. recovery culture).

## A.2 Differentiation and reprogramming protocol

Differentiation protocol covers the directed-differentiation envelope per target lineage (osteogenic / chondrogenic / adipogenic for MSC; cardiomyogenic / neural / hepatic / pancreatic for iPSC-derived), the chemical-defined-medium envelope (inductive cocktails with the documented concentrations and time-courses), the growth-factor cocktail envelope per Phase 1 §A.2, the marker-validation envelope (positive and negative markers at each differentiation stage), and the maturation-end-point envelope. Reprogramming protocol for iPSC covers the reprogramming-vector envelope (Sendai-virus / episomal-plasmid / mRNA / piggyBac), the transgene-clearance envelope, and the post-reprogramming pluripotency-validation envelope (teratoma / PluriTest / qPCR + immunostaining of pluripotency markers).

## A.3 Implantation and clinical-administration protocol

Implantation protocol covers the route-of-administration envelope (intra-articular / intra-muscular / intra-coronary / intra-venous / intra-thecal / topical-on-scaffold / surgical-site-implant), the dose-escalation envelope per the trial protocol, the per-administration safety-monitoring envelope (vital-sign monitoring, cytokine-release-syndrome monitoring where applicable, immediate-immunogenicity monitoring), the post-administration follow-up envelope (typically 12-month safety follow-up plus longer-term efficacy follow-up out to 5-15 years for permanent grafts), and the sympathetic-nervous-system effects monitoring for cellular therapies that may modulate systemic immune responses.

## A.4 Vascularization-and-engraftment protocol

Vascularization-and-engraftment protocol covers the host-vasculature integration envelope (cross-reference WIA-BIO-006 tissue-engineering Phase 3 §A.3 vascularization for the technical detail), the per-application engraftment-assessment envelope (imaging-based — MRI / CT / ultrasound / PET with cell-tracker label; biomarker-based — circulating donor-DNA signature; functional-based — tissue-function recovery metric), and the failure-mode envelope (engraftment-failure, immune-rejection, off-target-engraftment, fibrotic encapsulation).

## A.5 Safety protocol — tumourigenicity and immunogenicity

Tumourigenicity protocol covers the pre-administration tumourigenicity envelope (soft-agar growth assay; immunodeficient-mouse xenograft per the operator's documented latency window — typical 16-26 weeks for iPSC-derived products), the genetic-stability envelope (karyotype + array-CGH or whole-genome-sequencing), the residual-undifferentiated-cell envelope (per ISO/TR 22916 cellular product reference + per-cell-type validated assay), and the post-administration cancer-surveillance envelope (annual surveillance for at least 15 years for iPSC-derived products). Immunogenicity protocol covers HLA-matching for allogeneic products, immunosuppressive-regimen envelope where applicable, and the per-patient anti-donor-antibody surveillance.

## A.6 Replay and integrity defence

Standard 96-bit nonce + 300-second skew window + 600-second seen-nonce cache for the registration and clinical-administration control plane. Audit-event records are signed at registration time and the signature chain is anchored into a Merkle tree per-tenant; chain breaks invalidate the consent envelope and trigger a forensic-review event. Cleanroom telemetry uses mTLS with per-suite monotonic counters.


---

## Z.1 Glossary, conformance, governance

A companion glossary at `https://wiastandards.com/regenerative-medicine/glossary/`
expands every term used throughout this Phase. The conformance
test suite at `https://github.com/WIA-Official/wia-regenerative-medicine-conformance`
walks every endpoint and protocol exchange. The reference container
at `wia/regenerative-medicine-host:1.0.0` ships every regenerative-medicine envelope and
endpoint with mock data so integrators can exercise the contract
before wiring real backends. The companion CLI at
`cli/regenerative-medicine.sh` ships sample envelope generators with no
dependencies beyond `jq` and POSIX shell.

## Z.2 Cross-standard composition (recap)

This Phase composes with WIA-OMNI-API for credential storage,
WIA-AIR-SHIELD for runtime trust list, WIA-SOCIAL Phase 3 §5 for
federation handshake, WIA-INTENT for workload intent declaration,
and (where personal data is processed) WIA Secure Enclave for
sealed-data envelopes. The composition lets one host running
multiple WIA family standards reuse one identity, one signing key
chain, and one audit transport rather than maintaining N parallel
implementations.

## Z.3 Implementation runbook

A first implementation typically follows: stand up the reference
container; run the conformance suite against it end-to-end;
replace the mock backend with a real backend one endpoint at a
time; wire audit-log replication out to the operations sink;
onboard a single trusted peer for federation; expand to multiple
peers; promote to production with the warning-envelope subscription
enabled and the runbook in §Z.5 followed.

## Z.4 Backwards-compatibility promise

Within the 1.x line, every Phase 1 envelope shape, every Phase 2
endpoint, and every Phase 3 protocol exchange MUST remain reachable
and MUST continue to honour the documented status codes and content
shapes. Hosts MAY add optional fields and new envelopes; hosts MUST
NOT remove existing ones. Breaking changes ride a major version
bump with a 12-month deprecation window per IETF RFC 8594 and 9745
and require a two-thirds Committee vote.

## Z.5 Closing implementer note

This Phase fits inside the WIA Standards four-Phase architecture:
Phase 1 envelopes are the wire-format contract; Phase 2 surfaces
them through HTTPS; Phase 3 wraps them in protocol exchanges that
cross trust boundaries; Phase 4 integrates with the broader
ecosystem. Regenerative-medicine deployments that follow this layering
inherit the per-Phase conformance gates and the cross-standard
composition behaviour described in Z.2.

弘益人間 — Benefit All Humanity.
